Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, Naiyer A., Hellmann, Matthew D., Snyder, Alexandra, Kvistborg, Pia, Makarov, Vladimir, Havel, Jonathan J., Lee, William, Yuan, Jianda +16 more·2015·Science

DOI 10.1126/science.aaa1348

Cited by (1,051)

Items 501–600 of 1,051

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L. Gulley, Arun Rajan, David Robert Spigel, Nicholas O. Iannotti, Jason Claud Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, Hans Juergen Grote et al. · 2017 · The Lancet Oncology
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
High-dose vitamin C enhances cancer immunotherapy
Magrì, Alessandro, Germano, Giovanni, Lorenzato, Annalisa, Lamba, Simona, Chilà, Rosaria, Montone, Monica, Amodio, Vito, Ceruti, Tommaso, Sassi, Francesco, Arena, Sabrina et al. · 2020 · Science Translational Medicine
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Marie Sholl, Fred R. Hirsch, David M. Hwang, Johan Botling, Fernando López‐Ríos, Lukas Bubendorf, Mari A. Mino-Kenudson, Anja Christiane Roden, Mary Beth Beasley, Alain Borczuk et al. · 2020 · Journal of Thoracic Oncology
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
Jin‐Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiaojie Lu, Jiansong Ji · 2020 · Biomarker Research
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, Dominik Georg Friedrich Wolf, Andreas Pircher · 2020 · Molecular Cancer
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
Brian David Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen, Hanbing An, Yuguang J. Ban, Hanchen Huang, Lily Hui-Ching Wang, Jamaal L. James, Justin Micah Balko et al. · 2021 · Nature Communications
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee, Adrian Gerard Murphy, Dung Thi Le, Luis Alberto Diaz · 2016 · The Oncologist
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang, Stefan Zimmermann, Kaushal Parikh, Aaron Scott Mansfield, Alex A. Adjei · 2019 · Mayo Clinic Proceedings
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes, Sean R. Caenepeel, Lawren C. Wu · 2016 · Trends in Immunology
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · 2021 · Nature reviews. Cancer
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal Ian Lindeman, Kathleen N. Moore, Shridar Ganesan, Christine Marie Lovly, Jane Perlmutter, Stacy W. Gray, Jimmy Hwang et al. · 2022 · Journal of Clinical Oncology
Pembrolizumab for the treatment of non-small cell lung cancer
Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy
Precision Oncology: Who, How, What, When, and When Not?
Lee Steven Schwartzberg, Edward S. Kim, David Liu, Deborah Schrag · 2017 · American Society of Clinical Oncology Educational Book
The Superior Efficacy of Anti-PD-1/PD-L1 Immunotherapy in KRAS-Mutant Non-Small Cell Lung Cancer that Correlates with an Inflammatory Phenotype and Increased Immunogenicity
Chengming Liu, Sufei Zheng, Runsen Jin, Xin‐Feng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei et al. · 2019 · Cancer Letters
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, Claire, Rudqvist, Nils-Petter, Elemento, Olivier, Formenti, Silvia C., Demaria, Sandra · 2019 · Genome Medicine
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
Min Yuen Teo, Richard Martin Bambury, Emily Craig Zabor, Emmet Jordan, Hikmat A Al‐Ahmadie, Mariel Elena Boyd, Nancy Bouvier, Stephanie Anne Mullane, Eugene K. Cha, Nitin Roper et al. · 2017 · Clinical Cancer Research
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Weiqiang Zhou, Shanchun Guo, Mingli Liu, Matthew E. Burow, Guangdi Wang · 2017 · Current Medicinal Chemistry
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Zhixian, Li, Mengyuan, Jiang, Zehang, Wang, Xiaosheng · 2018 · Translational Oncology
The genomic landscape of breast cancer and its interaction with host immunity
Stephen James Luen, Balaji Virassamy, Peter Stephen Savas, Roberto Salgado, Sherene Loi · 2016 · The Breast
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
Corrie Painter, Esha Jain, Brett N. Tomson, Michael Dunphy, Rachel E. Stoddard, Beena S. Thomas, Alyssa L. Damon, Shahrayz Shah, Dewey Kim, Jorge Gómez Tejeda Zañudo et al. · 2020 · Nature Medicine
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek Dinkarnath Garg, Sanket More, Nicole Rufo, Odeta Meçe, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2017 · OncoImmunology
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Glenn J. Hanna, Patrick Hall Lizotte, Megan E. Cavanaugh, Frank C. Kuo, Priyanka Shivdasani, Alexander Frieden, Nicole Grace Chau, Jonathan Daniel Schoenfeld, Jochen H. Lorch, Ravindra Uppaluri et al. · 2018 · JCI Insight
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Yu, Helena A., Suzawa, Ken, Jordan, Emmet, Zehir, Ahmet, Ni, Ai, Kim, Ryan, Kris, Mark G., Hellmann, Matthew D., Li, Bob T., Somwar, Romel et al. · 2018 · Clinical Cancer Research
Diagnosis and Molecular Classification of Lung Cancer
Jaime Rodriguez‐Canales, Edwin Roger Parra-Cuentas, Ignacio Ivan Wistuba · 2016 · Cancer treatment and research
Emerging role of tumor cell plasticity in modifying therapeutic response
Siyuan Qin, Jingwen Jiang, Yi Lü, Edouard Collins Nice, Canhua Huang, Jian Zhang, Weifeng He · 2020 · Signal Transduction and Targeted Therapy
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael Joe Duffy, John Paul Crown · 2019 · Clinical Chemistry
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Arnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau Comas, Philippe J. Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen et al. · 2020 · European Respiratory Journal
Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress
Zhusheng Huang, Yuxiang Wang, Dan Yao, Jinhui Wu, Yiqiao Hu, Ahu Yuan · 2021 · Nature Communications
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia et al. · 2021 · Cancer Discovery
Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Siddhartha H. K. Devarakonda, Federico Rotolo, Ming‐Sound Tsao, Irena Lanc, Elisabeth M. Brambilla, Ashiq Masood, Ken André Olaussen, Robert S. Fulton, Shingo Sakashita, Anne Mc Leer et al. · 2018 · Journal of Clinical Oncology
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles, Xiaoyun Liao, Lynette Marie Sholl, Scott J. Rodig, Gordon James Freeman, Mohit Butaney, Christine Lydon, Suzanne Eleanor Dahlberg, Frank Stephen Hodi, Geoffrey R. Oxnard et al. · 2015 · Journal of Thoracic Oncology
Antitumour dendritic cell vaccination in a priming and boosting approach
Alexandre Harari, Michele Graciotti, Michal Bassani‐Sternberg, Lana Elias Kandalaft · 2020 · Nature Reviews Drug Discovery
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju‐Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong‐Wan Kim, Doo Hyun Chung, Dae Seog Heo · 2016 · Clinical Cancer Research
Clinical Implications of Genomic Discoveries in Lung Cancer
Charles Swanton, Ramaswamy Govindan · 2016 · New England Journal of Medicine
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Alexander C. Ou, W.K. Alfred Yung, Nazanin Majd · 2020 · International Journal of Molecular Sciences
Future directions in the treatment of osteosarcoma
Michael William Bishop, Katherine A. Janeway, Richard Greg Gorlick · 2015 · Current Opinion in Pediatrics
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson, Eric Allan Severson, Laurie M. Gay, Jo‐Anne Vergilio, Julia Andrea Elvin, James H. Suh, Sugganth Daniel, Mandy Covert, Garrett Michael Frampton, Sigmund H. Hsu et al. · 2017 · The Oncologist
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer
Seong‐Keun Yoo, Young Shin Song, Eun Kyung Lee, Jinha Hwang, Hwan Hee Kim, Gyeongseo Jung, Young A Kim, Su‐jin Kim, Sun Wook Cho, Jae‐Kyung Won et al. · 2019 · Nature Communications
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, David J., Johannessen, Cory M., Garraway, Levi A. · 2018 · Cancer Cell
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Zhenyu Ding, Qing Li, Rui Zhang, Li Xie, Yang Shu, Song Gao, Peipei Wang, Xiaoqing Su, Yun Qin, Yuelan Wang et al. · 2021 · Signal Transduction and Targeted Therapy
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
Anqi Lin, Ting Wei, Hui Meng, Peng Luo, Jian Zhang · 2019 · Molecular Cancer
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Koga, Takamasa, Suda, Kenichi, Fujino, Toshio, Ohara, Shuta, Hamada, Akira, Nishino, Masaya, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Arita, Takeo et al. · 2021 · Journal of Thoracic Oncology
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, Wafik S., Goldberg, Richard M., Lenz, Heinz‐Josef, Shields, Anthony F., Gibney, Geoffrey T., Tan, Antoinette R., Brown, Jubilee, Eisenberg, Burton, Heath, Elisabeth I., Phuphanich, Surasak et al. · 2019 · CA: A Cancer Journal for Clinicians
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U. Dafni, Olivier Alain Michielin, Silvia Martin Lluesma, Zoi Tsourti, Varvara Polydoropoulou, Dimitris Karlis, Michal Judith Besser, John B.A.G. Haanen, Inge Marie Svane, Pamela S. Ohashi et al. · 2019 · Annals of Oncology
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
Jae-Won Cho, Min Hee Hong, Sang‐Jun Ha, Young‐Joon Kim, Byoung Chul Cho, Insuk Lee, Hye Ryun Kim · 2020 · Experimental & Molecular Medicine
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Diego Chowell, Seong‐Keun Yoo, Cristina Valero, Alessandro Pastore, Chirag Krishna, Mark Lee, Douglas Robert Hoen, Hongyu Shi, Daniel W. Kelly, Neal Patel et al. · 2021 · Nature Biotechnology
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio, Thomas J. George, Richard Francis Dunne, Garrett Michael Frampton, James X. Sun, Kyle A. Gowen, Mark Kennedy, Joel R. Greenbowe, Alexa Betzig Schrock, Aram F. Hezel et al. · 2018 · Journal of Gastrointestinal Oncology
A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Hagma H. Workel, Joyce M. Lubbers, Roland R. Arnold, Thalina M. Prins, Pieter van der Vlies, Kim de Lange, Tjalling Bosse, Inge C. van Gool, Florine A. Eggink, Maartje C.A. Wouters et al. · 2019 · Cancer Immunology Research
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Michael Siavash Khodadoust, Niclas Olsson, Lisa E. Wagar, Ole Audun Werner Haabeth, Binbin Chen, Kavya Swaminathan, Keith Rawson, Chih Long Liu, David F. Steiner, Peder J. Lund et al. · 2017 · Nature
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas, Eric D. Routh, Ashok Pullikuth, Guangxu Jin, Jing Su, Jeff W. Chou, Katherine A. Hoadley, Cristin Gregor Print, Nicholas S. Knowlton, Michael A. Black et al. · 2018 · OncoImmunology
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
Marc Oliva, Anna Spreafico, Miren Taberna, Laia Alemany, Bryan A. Coburn, Ricard Mesı́a, Lillian L. Siu · 2018 · Annals of Oncology
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Gordon Beattie, Andrew Rowan, Désirée Schnidrig, R. Houston Thompson, Fiona Byrne, Stuart D. Horswell et al. · 2021 · Cancer Cell
Challenges in developing personalized neoantigen cancer vaccines
Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe · 2023 · Nature reviews. Immunology
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang, Jonathan E. Schoenhals, Ailin Li, David R. Valdecanas, Huiping Ye, Fenglin Zang, Chad Z. Tang, Ming Tang, Chang‐Gong Liu, Xiuping Liu et al. · 2016 · Cancer Research
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes · 2015 · Nature Reviews Clinical Oncology
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
Shogo Kumagai, Yosuke Togashi, Chika Sakai, Akihito Kawazoe, Masahito Kawazu, Toshihide Ueno, Eiichi Sato, Takeshi Kuwata, Takahiro Kinoshita, Masami Yamamoto et al. · 2020 · Immunity
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC
Shiwei Chen, Shu‐Qiang Zhu, Xu Pei, Bai‐Quan Qiu, Dian Xiong, Xiang Long, Kun Lin, Feng Lü, Jianjun Xu, Yongbing Wu · 2021 · Molecular Cancer
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Shengjie Tang, Chao Qin, Haiyang Hu, Tao Liu, Yiwei He, Haiyang Guo, Hang Yan, Jun Zhang, Shoujun Tang, Haining Zhou · 2022 · Cells
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
María Ochoa de Olza, Blanca Navarro Rodrigo, Stefan Zimmermann, George Coukos · 2020 · The Lancet Oncology
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer
Morganti, Stefania, Tarantino, Paolo, Ferraro, Emanuela, D’Amico, Paolo, Duso, Bruno Achutti, Curigliano, Giuseppe · 2019 · Advances in Experimental Medicine and Biology
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
Marius Ilié, Véronique Hofman, Manfred Dietel, Jean‐Charles Soria, Paul M Hofman · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Patrick Alexander Ott, Sarina Anne Piha-Paul, Pamela N. Münster, Michael Jon Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily W. Chan et al. · 2017 · Annals of Oncology
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles Cameron Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère et al. · 2019 · Cell Research
Biomarkers for immunotherapy response in head and neck cancer
Niki Gavrielatou, S Doumas, Panagiota Economopoulou, Periklis G. Foukas, Amanda Psyrri · 2020 · Cancer Treatment Reviews
Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Naoya Kitamura, Shinya Sento, Yasumasa Yoshizawa, Eri Sasabe, Yasusei Kudo, Tetsuya Yamamoto · 2020 · International Journal of Molecular Sciences
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard J. Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey Alan Sosman, Giuseppe Procopio, Elizabeth R. Plimack et al. · 2017 · European Urology
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Michael J. Grant, Roy S. Herbst, Sarah B. Goldberg · 2021 · Nature Reviews Clinical Oncology
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
Host tissue determinants of tumour immunity
Hélène Salmon, Romain Remark, Sacha Gnjatic, Miriam Mérad · 2019 · Nature reviews. Cancer
Lung Cancer Biomarkers
Pamela Andrea Villalobos, Ignacio Ivan Wistuba · 2016 · Hematology/Oncology Clinics of North America
Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients
Ilseon Hwang, Jeong Won Kim, Kris Ylaya, Eun Joo Chung, Haruhisa Kitano, Candice D. Perry, Jun Hanaoka, Junya Fukuoka, Joon‐Yong Chung, Stephen M. Hewitt · 2020 · Journal of Translational Medicine
Big data in basic and translational cancer research
Jiang, Peng, Sinha, Sanju, Aldape, Kenneth, Hannenhalli, Sridhar, Sahinalp, Cenk, Ruppin, Eytan · 2022 · Nature Reviews Cancer
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
Shixiang Wang, Mingming Jia, Zaoke He, Xuesong Liu · 2018 · Oncogene
Circulating biomarkers in patients with glioblastoma
Juliana Müller Bark, Arutha Kulasinghe, Benjamin Chua, Bryan W. Day, Chamindie Punyadeera · 2019 · British Journal of Cancer
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Mark M. Yarchoan, Edward John Gane, Thomas Urban Marron, Renzo F. Perales-Linares, Jian Yan, Neil S. Cooch, Daniel H. Shu, Elana Judith Fertig, Luciane Tsukamoto Kagohara, Gabor T. Bartha et al. · 2024 · Nature Medicine
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
Marzia Del Re, Riccardo Marconcini, Giulia Pasquini, Eleonora Rofi, Caterina Vivaldi, Francesco Bloise, Giuliana Restante, Elena Arrigoni, Chiara Caparello, Maria Grazia Bianco et al. · 2018 · British Journal of Cancer
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Bianca Rojo, Karen A. Autio, Deborah J. L. Wong, Manish R. Patel et al. · 2018 · Cancer Cell
cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
Wang, Zining, Chen, Jiemin, Hu, Jie, Zhang, Hongxia, Xu, Feifei, He, Wenzhuo, Wang, Xiaojuan, Li, Mengyun, Lu, Wenhua, Zeng, Gucheng et al. · 2019 · Journal of Clinical Investigation
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
Vivek Subbiah, David B. Solit, Timothy An-thy Chan, Razelle Kurzrock · 2020 · Annals of Oncology
Immuno-genomic landscape of osteosarcoma
Wu, Chia-Chin, Beird, Hannah C., Andrew Livingston, J., Advani, Shailesh, Mitra, Akash, Cao, Shaolong, Reuben, Alexandre, Ingram, Davis, Wang, Wei-Lien, Ju, Zhenlin et al. · 2020 · Nature Communications
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
Eduardo Bonavita, Christian P. Bromley, Gustav Jonsson, Victoria S. Pelly, Sudhakar Sahoo, Katherine Walwyn-Brown, Sofia Mensurado, Agrin Moeini, Eimear Flanagan, Charlotte R. Bell et al. · 2020 · Immunity
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio Ivan Wistuba, David J. Kwiatkowski, Dwight Hall Owen, Yan Tang, Bruce Evan Johnson, Jay M. Lee et al. · 2022 · Nature Medicine
Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports
The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero, Mark Andrew Lee, Douglas Robert Hoen, Jingming Wang, Zaineb Nadeem, Neal Patel, Michael Andrew Postow, Alexander Noor Shoushtari, George Plitas, Vinod P. Balachandran et al. · 2021 · Nature Genetics
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Zheng, Xichen, Fang, Zhaoxu, Liu, Xiaomei, Deng, Shengming, Zhou, Pei, Wang, Xuexiang, Zhang, Chenglin, Yin, Rongping, Hu, Haitian, Chen, Xiaolan et al. · 2018 · Journal of Clinical Investigation
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Giulia Mazzaschi, Denise Madeddu, Angela Falco, Giovanni Bocchialini, Matteo Goldoni, Francesco Sogni, Giovanna Armani, Costanza Annamaria Lagrasta, Bruno Lorusso, Chiara Mangiaracina et al. · 2017 · Clinical Cancer Research
Prevalence ofPDL1Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron Michael Goodman, David Eric Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett Michael Frampton, Scott Michael Lippman, Caitlin F. Connelly, David A. Fabrizio, Vincent A. Miller et al. · 2018 · JAMA Oncology
Alternative mRNA splicing in cancer immunotherapy
Luke Frankiw, David Baltimore, Guideng Li · 2019 · Nature reviews. Immunology
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato et al. · 2020 · Clinical Cancer Research
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen · 2022 · Frontiers in Immunology
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, Shin Foong, Young, Arabella, Jacquelot, Nicolas, Yamazaki, Takahiro, Enot, David, Zitvogel, Laurence, Smyth, Mark J. · 2015 · Cancer Research
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
Takehito Shukuya, David Paul Carbone · 2016 · Journal of Thoracic Oncology
Therapeutic targeting of regulatory T cells in cancer
Feng Shan, Ashwin Somasundaram, Tullia Carmela Bruno, Creg J. Workman, Dario A.A. Vignali · 2022 · Trends in cancer
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, Gjada Criscuolo, Maria Triassi, Domenico Bonaduce, Gianni Marone, Carlo Gabriele Tocchetti · 2017 · ESMO Open
iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
Frank M. Cichocki, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Hongbo Wang, Katie Tuininga, Martin Felices, Zachary Davis, Laura E. Bendzick et al. · 2020 · Science Translational Medicine
Progress and challenges of immunotherapy in triple-negative breast cancer
Yinxing Zhu, Xuedan Zhu, Cuiju Tang, Xiaoxiang Guan, Wenwen Zhang · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb‐Esfahani, Catarina Alisa Kunze, Hagen Kulbe, Jalid Sehouli, Stephan Wienert, Judith Lindner, Jan Budczies, Michael Ludwig Bockmayr, Manfred Dietel, Carsten Denkert et al. · 2015 · Oncotarget